TABLE 1.
Baseline patient characteristics.
| Group | Derivation cohort (627) | Validation cohort (304) | ||
| Study group (322) | Control group (305) | Study group (159) | Control group (145) | |
| Subtype | IS (322) | HS (176) | IS (159) | HS (60) |
| SAH (45) | SAH (21) | |||
| SDH (62) | SDH (14) | |||
| Brain tumor–associated ICH (22) | Brain tumor–associated ICH (11) | |||
| – | SM (39) | |||
| Age, y | 63 (52.25–73.75) | 53 (43–64) | 65 (54–75) | 54 (45–65) |
| Sex (female) | 114 (35.40%) | 99 (32.46%) | 55 (34.59%) | 50 (34.48%) |
| Drinking | 136 (42.24%) | 103 (33.77%) | 63 (39.62%) | 48 (33.10%) |
| Smoking | 148 (45.96%) | 100 (32.79%) | 78 (49.06%) | 48 (33.10%) |
| Height | 163 (157–170) | 165 (159–170) | 165 (158–170) | 165 (158–170) |
| Weight | 65 (55.62–70) | 65 (55–72) | 65 (59.50–72.50) | 65 (61–75) |
| HP | 223 (69.25%) | 201 (65.90%) | 113 (71.07%) | 102 (70.34%) |
| DM | 114 (35.40%) | 25 (8.20%) | 42 (26.42%) | 13 (8.97%) |
| HLP | 51 (15.84%) | 4 (1.31%) | 18 (11.32%) | 1 (0.69%) |
| RBC | 4.63 (4.21–4.96) | 4.58 (4.17–5.00) | 4.59 (4.28–4.93) | 4.46 (4.02–4.92) |
| Hct | 0.41 (0.38–0.44) | 0.41 (0.38–0.45) | 0.41 (0.38–0.44) | 0.41 (0.37–0.44) |
| Hb | 139 (127–150) | 139 (125–152) | 137 (124–149.50) | 137 (123–149) |
| RDW-CV | 13.50 (12.90–14.30) | 13.60 (13.00–14.50) | 13.60 (13.00–14.60) | 13.70 (13.00–14.40) |
| RDW-SD | 43.70 (41.02–46.68) | 43.90 (41.40–46.50) | 44.20 (41.70–47.65) | 44.10 (40.90–47.30) |
| WBC | 7.63 (6.20–9.39) | 10.80 (7.95–14.37) | 7.63 (6.56–9.32) | 10.92 (7.41–13.29) |
| PLT | 181 (134.25–219.75) | 172 (130–213) | 177 (137.50–230) | 165 (124–222) |
| PT | 11.50 (10.90–12.30) | 11.30 (10.70–11.90) | 11.00 (10.50–11.80) | 11.20 (10.60–12.00) |
| APTT | 27.50 (25.22–29.70) | 26.00 (23.80–28.20) | 26.50 (24.95–28.30) | 25.20 (23.40–27.60) |
| TT | 18.20 (17.50–18.90) | 18.00 (17.30–18.90) | 17.90 (17.30–18.60) | 18.00 (17.30–18.60) |
| FIB | 2.85 (2.40–3.58) | 2.58 (2.07–3.23) | 2.83 (2.41–3.42) | 2.60 (2.14–3.35) |
| AT-III | 90.50 (82.43–99.60) | 90.10 (81.70–98.90) | 87.90 (80.65–95.20) | 89.60 (78.40–98.10) |
| D-dimer | 0.44 (0.23–1.03) | 0.73 (0.31–1.68) | 0.63 (0.27–1.64) | 0.64 (0.27–1.38) |
| TBIL | 12.65 (8.83–18.98) | 13.00 (9.50–18.00) | 12.00 (9.50–17.00) | 11.00 (8.60–15.90) |
| DBIL | 4.65 (3.30–6.88) | 4.90 (3.30–6.50) | 3.90 (2.80–5.75) | 3.90 (3.00–5.70) |
| IBIL | 7.95 (5.50–11.78) | 8.10 (5.80–11.20) | 8.20 (6.15–11.20) | 6.90 (5.10–10.30) |
| TP | 71.70 (68.32–75.60) | 72.00 (68.40–77.00) | 72.50 (68.60–75.90) | 72.50 (68.40–76.40) |
| Alb | 42.65 (39.80–45.00) | 43.00 (40.50–46.00) | 42.70 (39.35–45.00) | 43.40 (40.10–45.60) |
| Globin | 29.05 (26.40–32.30) | 29.10 (26.00–32.10) | 29.60 (26.95–32.40) | 29.80 (25.80–32.80) |
| CREA | 74 (61–91) | 72 (60–86) | 72 (63–86) | 67 (55–82) |
| URIC | 338 (273.25–403) | 318 (248–409) | 329 (263.50–407.50) | 315 (243–382) |
| GLU | 6.75 (5.88–8.36) | 7.46 (6.13–9.72) | 6.74 (5.93–8.61) | 7.76 (6.37–9.75) |
| ALT | 19 (13–27.75) | 19 (14–30) | 19 (13.50–31) | 20 (15–28) |
| AST | 20.50 (17–27) | 23 (18–31) | 20 (16–27) | 22 (17–28) |
| ALP | 81 (67–96) | 80 (66–97) | 83 (68–97.50) | 77 (67–103) |
| CK | 86 (56–131.75) | 110 (72–176) | 86 (56.50–128) | 95 (64–125) |
| GGT | 29 (18–46.75) | 25 (15–50) | 28 (19–51.50) | 31 (16–53) |
| LDH | 185 (155–220) | 205 (176–252) | 185 (159–215) | 202 (177–240) |
| HBDH | 148 (125–179.75) | 167 (142–203) | 151 (132.50–180) | 165 (144–198) |
| TG | 1.39 (0.96–2.01) | 1.16 (0.75–1.82) | 1.27 (0.95–1.92) | 1.08 (0.73–1.49) |
| CHOL | 4.29 (3.54–5.09) | 4.30 (3.71–4.93) | 4.22 (3.37–5.08) | 4.25 (3.69–4.96) |
| HDL-C | 1.17 (0.93–1.42) | 1.27 (0.98–1.55) | 1.12 (0.92–1.38) | 1.32 (1.08–1.62) |
| LDL-C | 2.48 (1.93–3.14) | 2.56 (2.04–3.09) | 2.64 (1.90–3.30) | 2.58 (2.07–3.14) |
| TBA | 3.50 (1.70–6.18) | 2.30 (1.10–4.50) | 3.20 (1.70–5.50) | 2.20 (1.20–4.80) |
| Urea | 5.60 (4.50–7.09) | 5.00 (3.90–6.30) | 5.10 (4.20–6.67) | 4.90 (3.90–6.26) |
Data are presented as n (%) for categorical variables and as median (upper and lower quartiles) for continuous variables. *p < 0.05.